Keros halts blood pressure treatment trial on safety issues (updated)

Keros Therapeutics

15/01/2025 11:54

(Adds share movement in paragraph 2, disease background in
paragraph 3, trial details in paragraphs 4-5)
       Jan 15 (Reuters) - Keros Therapeutics  KROS.O  said on
Wednesday it would voluntarily halt testing of its experimental
blood pressure treatment due to safety concerns during a
mid-stage trial.
    Its shares fell 8% to $11.52 in premarket trading. 
    The company was testing the therapy, cibotercept, in
patients with pulmonary arterial hypertension — a rare,
progressive lung disease that causes high blood pressure in the
pulmonary arteries.
    Keros said it observed excess fluid build up around the
heart in patients. It is terminating the trial early and will
monitor patients who were part of the study.
    The company expects to present clinical data from the trial
in the second quarter of 2025.

 (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)
 ((Christy.Santhosh@thomsonreuters.com))